 | • レポートコード：MRC2304L229 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、世界の抗生物質市場規模が2021年に372.5億ドル、2022年に395.7億ドルとなり、その後2027年までにCAGR 6.36％で成長して539.5億ドルに達すると予測しています。当書は、抗生物質の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、作用機序別分析（細胞壁合成阻害剤、DNA合成阻害剤、ミコール酸阻害剤、タンパク質合成阻害剤、RNA合成阻害剤）、薬剤分類別分析（アミノグリコシド、カルバペネム、セファロスポリン、フルオロキノロン、マクロライド）、範囲別分析（広域抗生物質、狭域抗生物質）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。また、当書には、Abbott Laboratories、Akron Incorporated、Amneal Pharmaceuticals LLC、Astellas Pharma, Inc.、Bausch Health Companies, Inc.、Bayer AG、Bristol-Myers Squibb Company、Cadila Healthcare Ltd.、Eli Lilly and Company、F. Hoffmann-La Roche AGなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の抗生物質市場規模：作用機序別 - 細胞壁合成阻害剤の市場規模 - DNA合成阻害剤の市場規模 - ミコール酸阻害剤の市場規模 - タンパク質合成阻害剤の市場規模 - RNA合成阻害剤の市場規模 ・世界の抗生物質市場規模：薬剤分類別 - アミノグリコシドの市場規模 - カルバペネムの市場規模 - セファロスポリンの市場規模 - フルオロキノロンの市場規模 - マクロライドの市場規模 ・世界の抗生物質市場規模：範囲別 - 広域抗生物質の市場規模 - 狭域抗生物質の市場規模 ・世界の抗生物質市場規模：地域別 - 南北アメリカの抗生物質市場規模 アメリカの抗生物質市場規模 カナダの抗生物質市場規模 ブラジルの抗生物質市場規模 ... - アジア太平洋の抗生物質市場規模 日本の抗生物質市場規模 中国の抗生物質市場規模 インドの抗生物質市場規模 韓国の抗生物質市場規模 台湾の抗生物質市場規模 ... - ヨーロッパ/中東/アフリカの抗生物質市場規模 イギリスの抗生物質市場規模 ドイツの抗生物質市場規模 フランスの抗生物質市場規模 ロシアの抗生物質市場規模 ... - その他地域の抗生物質市場規模 ・競争状況 ・企業情報 |
The Global Antibiotics Market size was estimated at USD 37.25 billion in 2021 and expected to reach USD 39.57 billion in 2022, and is projected to grow at a CAGR 6.36% to reach USD 53.95 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Antibiotics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Action Mechanism, the market was studied across Cell Wall Synthesis Inhibitors, DNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Protein Synthesis Inhibitors, and RNA Synthesis Inhibitors.
Based on Drug Class, the market was studied across Aminoglycosides, Carbapenem, Cephalosporin, Fluoroquinolone, Macrolides, Penicillin, and Sulfonamides.
Based on Spectrum, the market was studied across Broad-spectrum Antibiotics and Narrow-spectrum Antibiotics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Antibiotics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antibiotics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antibiotics Market, including Abbott Laboratories, Akron Incorporated, Amneal Pharmaceuticals LLC, Astellas Pharma, Inc., Bausch Health Companies, Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Healthcare Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, KYORIN Holdings, Inc., LG Chem Ltd., Lupin Limited, Melinta Therapeutics, Inc., Merck & Co., Inc., MerLion Pharmaceuticals GmbH, Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Antibiotics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antibiotics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antibiotics Market?
4. What is the competitive strategic window for opportunities in the Global Antibiotics Market?
5. What are the technology trends and regulatory frameworks in the Global Antibiotics Market?
6. What is the market share of the leading vendors in the Global Antibiotics Market?
7. What modes and strategic moves are considered suitable for entering the Global Antibiotics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Patients Suffering from Infectious Diseases
5.1.1.2. Development of Novel Strategies for New Antibiotics and a Large Number of Clinical Trials
5.1.1.3. Extended Consumption in Low and Middle-Income Countries
5.1.2. Restraints
5.1.2.1. Misuse of Antibiotics
5.1.3. Opportunities
5.1.3.1. Advanced Prospect Molecules and Novel Combination Therapies to Treat Antibiotic-Resistant Microbial Infections
5.1.3.2. Growing in R&D and Investments for New Drugs
5.1.4. Challenges
5.1.4.1. Side Effects Caused by the Usage of Antibiotic Drugs
5.2. Cumulative Impact of COVID-19
6. Antibiotics Market, by Action Mechanism
6.1. Introduction
6.2. Cell Wall Synthesis Inhibitors
6.3. DNA Synthesis Inhibitors
6.4. Mycolic Acid Inhibitors
6.5. Protein Synthesis Inhibitors
6.6. RNA Synthesis Inhibitors
7. Antibiotics Market, by Drug Class
7.1. Introduction
7.2. Aminoglycosides
7.3. Carbapenem
7.4. Cephalosporin
7.5. Fluoroquinolone
7.6. Macrolides
7.7. Penicillin
7.8. Sulfonamides
8. Antibiotics Market, by Spectrum
8.1. Introduction
8.2. Broad-spectrum Antibiotics
8.3. Narrow-spectrum Antibiotics
9. Americas Antibiotics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antibiotics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antibiotics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Akron Incorporated
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Amneal Pharmaceuticals LLC
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Astellas Pharma, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bausch Health Companies, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bayer AG
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bristol-Myers Squibb Company
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cadila Healthcare Ltd.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Eli Lilly and Company
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. F. Hoffmann-La Roche AG
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Johnson & Johnson
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. KYORIN Holdings, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. LG Chem Ltd.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Lupin Limited
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Melinta Therapeutics, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck & Co., Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. MerLion Pharmaceuticals GmbH
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Mylan N.V.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Novartis International AG
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Pfizer Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Sanofi S.A.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Shionogi & Co., Ltd.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Sun Pharmaceutical Industries Limited
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Teva Pharmaceutical Industries Ltd.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing